Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0013911 (
emaciation
)
1,059
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The presence of cachectin or tumor necrosis factor (TNF) associated with hypertriglyceridemia was demonstrated in the serum of patients with pulmonary tuberculosis. The hyperlipidemia that accompanies this infection may be mediated by the TNF inhibition of
lipoprotein lipase
activity. This sequence of events may be sufficient to explain, in part, the complex metabolic changes and
emaciation
observed in tuberculosis patients.
...
PMID:The role of cachectin/TNF in the pathogenesis of tuberculosis. 314 96
The Leydig cell tumor has been reported to produce tumor necrosis factor (TNF) and induce cachexia in rats. TNF is thought to reduce
lipoprotein lipase
(
LPL
) activity, decrease fat deposits, induce
emaciation
, and worsen cachexia. Therefore, we thought
emaciation
might be prevented and thus cachexia improved by increasing
LPL
activity. We administered NO-1886, a
lipoprotein lipase
activator, to rats bearing Leydig cell tumor and observed its effect on improving the cachexia induced by the tumor. In Leydig cell tumor-bearing rats, the
emaciation
progressed after tumor inoculation and the general condition worsened daily. Plasma levels of total protein, albumin, and glucose, which are biological parameters of malnutrition, were found to decrease soon after tumor inoculation in tumor-bearing rats. In contrast, rats given NO-1886 showed less malnutrition than tumor-bearing rats.
LPL
activity of rat adipose tissue was decreased, the weight of adipose tissue was decreased, carcass weight was reduced, and food consumption was decreased after Leydig cell tumor inoculation. NO-1886 increased adipose tissue
LPL
activity and suppressed the decrease in the weight of adipose tissue, carcass weight, and food consumption due to cachexia without influencing tumor growth. The present results suggest that the novel compound NO-1886 may suppress carcass weight loss in rats bearing Leydig cell tumor by suppressing the decrease in food consumption and
LPL
activity.
...
PMID:Suppression of carcass weight loss in cachexia in rats bearing Leydig cell tumor by the novel compound NO-1886, a lipoprotein lipase activator. 944 Apr 86